undamentalytics Newsletter
Sign in

Insight Molecular Diagnostics Inc. cash flow statement

In fiscal 2025, Insight Molecular Diagnostics Inc.'s operations generated −$22.2m of cash; it spent $3.2m on capital projects, leaving free cash flow of −$25.4m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−4−26−36−46−23−21−22−27
Depreciation and amortisation00122222
Stock-based pay257103223
Capital spending11240134
Free cash flow−5−27−38−50−24−21−25−31
Free cash flow after stock pay−7−32−45−60−26−23−28−34
Shares issued1218653314262926

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ICU vs IMDXFEMY vs IMDXIMDX vs PLSE

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Insight Molecular Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Insight Molecular Diagnostics Inc.